March 15, 2026. 5 cannabis news items, curated from live RSS feeds. Sorted by relevance score.
Does Cannabis Use by Older Adults Accelerate Mental Decline? – Labroots
# Summary This article examines research on whether cannabis use in older adults contributes to accelerated cognitive decline and discusses structural variations in synthetic cannabinoid compounds.
Read more →Study Found CBD and CBG May Counter Fatty Liver Disease | Cannabis Sciences
# Article Summary Research indicates cannabidiol (CBD) and cannabigerol (CBG) may have therapeutic potential in treating fatty liver disease, suggesting novel pharmacological approaches to hepatic lipid accumulation.
Read more →Connect to the Capitol: Budget battle, Clyburn to run again, tussle over THC | WTMA-AM
# Summary This article covers South Carolina legislative developments including budget negotiations, Representative Clyburn’s reelection plans, and regulatory discussions regarding THC products.
Read more →Breakthrough Laboratory Device Revolutionizes Cannabinoid Extraction and … – Tech Times
# Summary A new laboratory device using protein spectroscopy improves cannabinoid extraction and analysis, advancing analytical methods for potential neurodegenerative disease research.
Read more →Medical cannabis may soon be available in Alabama, almost five years after authorization
Alabama is implementing medical cannabis availability nearly five years after legislative authorization, with patient advocates like Amanda Taylor involved in the regulatory process.
Read more →Clinical Commentary
# Clinical Reflection These items collectively reflect an evolving landscape where cannabis medicine is moving toward regulatory implementation while evidence generation continues in specific therapeutic areas, particularly around metabolic and neurodegenerative conditions. The focus on cannabinoid-specific effects like CBD and CBG for fatty liver disease, paired with legitimate concerns about cognitive impacts in older populations, underscores that responsible prescribing requires us to move beyond cannabis as a monolithic entity and instead individualize based on cannabinoid profile, patient demographics, and specific indications. The parallel advancement of extraction technology alongside state-level policy shifts suggests that within the next few years, clinicians will have both better access to standardized formulations and a growing body of pharmacological evidence to inform evidence-based practice, though we must remain vigilant about gaps in long-term safety data.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: